SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 68692.
  • 2
    Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 33744.
  • 3
    Holt WS Jr, Mazzuca SA. Prescribing behaviors of family physicians in the treatment of osteoarthritis. Fam Med 1992; 24: 5247.
  • 4
    Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 1998; 25: 40816.
  • 5
    Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 2000; 27: 164855.
  • 6
    Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 48896.
  • 7
    Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 24339.
  • 8
    Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 16759.
  • 9
    Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 16572.
  • 10
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 78796.
  • 11
    Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 20939.
  • 12
    Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 13
    Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 15306.
  • 14
    Henrich WL, Agodoa LE, Barrett B, Bennett WM, Blantz RC, Buckalew VM Jr, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 1625.
  • 15
    Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, et al, Canadian NSAID Consensus Participants. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. CMAJ 1996; 155: 7788.
  • 16
    Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: the second Canadian consensus conference. Can J Clin Pharmacol 2000; 7 Suppl A: 4A16A.
  • 17
    American College of Rheumatology Subcommittee Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 18
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 71322.
  • 19
    Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 153540.
  • 20
    Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 15416.
  • 21
    Eccles M, Freemantle N, Mason J, The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998; 317: 52630.
  • 22
    U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 15760.
  • 23
    Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002; 29: 150110.
  • 24
    Lanza FL, Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 203746.
    Direct Link:
  • 25
    MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator Set. Arthritis Rheum 2004; 51: 193202.
  • 26
    Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001; 135: 64752.
  • 27
    Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992; 152: 128995.
  • 28
    Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002; 29: 80412.
  • 29
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 30
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al, Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 124755.
  • 31
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 32
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 168190.
    Direct Link:
  • 33
    Lu H. Statistical Reviewer Briefing Document for the Advisory Committee. Accessed January 15, 2002. URL: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc.
  • 34
    Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 Suppl 56:18–24.
  • 35
    Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 53945.
  • 36
    Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30: 43844.
  • 37
    Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al, Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 77683.
  • 38
    Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al, The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 3707.
  • 39
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 19218.
  • 40
    Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 29983003.
  • 41
    Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al, Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 17817.
  • 42
    McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 118.
  • 43
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095105.
  • 44
    Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA 2001; 286: 31521.
  • 45
    Jick H, Derby LE, Garcia Rodriguez LA, Jick SS, Dean AD. Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study. Pharmacotherapy 1993; 13: 2127.
  • 46
    Fox DA, Jick H. Nonsteroidal anti-inflammatory drugs and renal disease. JAMA 1984; 251: 1299300.
  • 47
    Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133: 19.
  • 48
    Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 7684.
  • 49
    Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 73541.
  • 50
    Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591602.
  • 51
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 190515.
  • 52
    Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22: 76773.
  • 53
    Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981; 141(3 Spec No): 3805.
  • 54
    Johnston SC, Pelletier LL Jr. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient: two case reports and a review of the literature. Medicine (Baltimore). 1997; 76: 18591.
  • 55
    Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002; 35: 87682.
  • 56
    Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337: 11127.
  • 57
    Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986; 104: 399404.
  • 58
    Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272: 184550.
  • 59
    Eriksson LS, Broome U, Kalin M, Lindholm M. Hepatotoxicity due to repeated intake of low doses of paracetamol. J Intern Med 1992; 231: 56770.
  • 60
    Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology 1994; 19: 11418.
  • 61
    Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: a meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156: 232132.
  • 62
    Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al, Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 71926.
  • 63
    Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al, Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 72734.
  • 64
    Lanza FL, Kochman RL, Geis GS, Rack EM, Deysach LG. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol 1991; 86: 17438.
  • 65
    Roth S, Agrawal N, Mahowald M, Montoya H, Robbins D, Miller S, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149: 7759.
  • 66
    Jiranek GC, Kimmey MB, Saunders DR, Willson RA, Shanahan W, Silverstein FE. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 1989; 96(2 Pt 2 Suppl ): 65661.
  • 67
    Ryan JR, Vargas R, Clay GA, McMahon FG. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 1987; 83: 416.
  • 68
    Silverstein FE, Kimmey MB, Saunders DR, Levine DS. Gastric protection by misoprostol against 1300 mg of aspirin: an endoscopic study. Dig Dis Sci 1986; 31(2 Suppl ): 137S41S.
  • 69
    Silverstein FE, Kimmey MB, Saunders DR, Surawicz CM, Willson RA, Silverman BA. Gastric protection by misoprostol against 1,300 mg of aspirin: an endoscopic dose-response study. Am J Med 1987; 83: 326.
  • 70
    Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000; 14: 52934.
  • 71
    Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994; 39: 97103.
  • 72
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 76972.
  • 73
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 166570.
  • 74
    Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997; 17: 21627.
  • 75
    Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged: a review of the literature. Med Decis Making 1999; 19: 42834.
  • 76
    Edwards A, Elwyn G, Covey J, Matthews E, Pill R. Presenting risk information: a review of the effects of “framing” and other manipulations on patient outcomes. J Health Commun 2001; 6: 6182.
  • 77
    Rothenberg R, Holcombe J. Guidelines for Monitoring of NSAIDs: who listened? J Clin Rheumatol 2000; 6: 25865.
  • 78
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 11837.
  • 79
    Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995; 21: 136.
  • 80
    Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 21926.
  • 81
    Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 82730.
  • 82
    de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1.
  • 83
    Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 8349.
  • 84
    Evans JM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995; 88: 5517.
  • 85
    Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990; 30: 71723.
  • 86
    Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9: 40312.
  • 87
    Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983; 143: 168793.
  • 88
    Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 73540.
  • 89
    Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153: 108993.